Miransertib

01/01/2019 - "Treatment with miransertib led to a complete remission of the cancer and a significant improvement in the patients' everyday life. "
10/01/2017 - "Tumor contrast enhancement was significantly decreased in the ARQ 092 group. "
10/01/2017 - "Furthermore, number of tumors was decreased by ARQ 092, which was associated with increased apoptosis and decreased proliferation. "
10/01/2017 - "MRI analyses showed that ARQ 092 significantly reduced overall tumor size. "
12/11/2015 - "ARQ 092 is an allosteric pan-AKT inhibitor under development for treatment in cancer. "

01/01/2019 - "We conclude that 5 mg/m2/day of miransertib is an appropriate starting point for future efficacy trials and that this agent shows promise of therapeutic efficacy in children with Proteus syndrome."
01/01/2019 - "We designed a non-randomized, phase 0/1 pilot study of miransertib in adults and children with Proteus syndrome to identify an appropriate dosage starting point for a future efficacy trial using a pharmacodynamic endpoint. "
01/01/2019 - "Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome."
12/01/2021 - "We present the 5-yr follow-up of an 18-yr-old male with Proteus syndrome treated with miransertib (MK-7075), an oral pan-AKT inhibitor. "
12/01/2021 - "Case report: five-year experience of AKT inhibition with miransertib (MK-7075) in an individual with Proteus syndrome."

10/01/2017 - "Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma."
02/16/2018 - "Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma."

01/01/2022 - "We confirmed the efficacy of miransertib in isolated human endothelial cells with genotypes spanning most of human low-flow vascular malformations."
01/01/2022 - "Using this model, we demonstrate that the AKT inhibitor miransertib both prevents and induces the regression of PI3K-driven vascular malformations. "
01/01/2022 - "The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib."

01/01/2017 - "In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy."